Case Report

Fatal pulmonary fibrosis complicating COVID-19 infection in preexistent emphysema✩✩

Massimiliano Mazzolini, MDa, Matteo Monari, MDa, Giulia Angeletti, MDa,*, Giorgia Dalpiaz, MDb, Alberto Rocca, MDa

aDepartment of Respiratory Medicine, Bellaria Hospital, Bologna, Italy
bDepartment of Radiology, Bellaria Hospital, Bologna, Italy

ARTICLE INFO

Article history:
Received 10 November 2020
Revised 28 November 2020
Accepted 29 November 2020
Available online 2 December 2020

Keywords:
Covid-19
SARS virus
Respiratory insufficiency
Pulmonary emphysema
Pulmonary fibrosis

ABSTRACT

Only a few earlier clinical radiologic reports exist describing post-COVID-19 pulmonary fibrosis. We report a case of 74-year-old woman referred with dizziness and hypoxemic respiratory failure with chest high resolution computer tomography (HRCT) showing ground glass opacities and emphysema. The patient was tested for Sars-CoV-2 and resulted positive, she was treated with medical therapy and supported with mechanical ventilation. Despite initial clinical and radiological improvements, subsequently the respiratory failure worsened as ground glass opacities evolved, with the appearance of combined pulmonary fibrosis and emphysema and the patient eventually died. Development of pulmonary fibrosis after SARS-CoV-2 infection and the overlap with preexistent emphysema could be a fatal complication.

Background

Sars-CoV-2 is an RNA virus of the beta-coronavirus family identified in December 2019 in Wuhan and it is known to cause COVID-19 disease, which could include interstitial pneumonia with evolution into acute respiratory distress syndrome in some individuals. World Health Organization (WHO) has classified SARS-CoV-2 as a pandemic. According to WHO data, SARS-CoV-2 has infected, as of November 8, 2020, more than 49 million people worldwide and has caused over 1 million confirmed deaths. The virus mainly affects men with a history of smoking and comorbidities including diabetes mellitus, arterial hypertension, obesity, heart disease, and chronic lung disease [1]. The SARS-CoV-2 virus has an incubation period between 3 and 7 days and about 80% of patients have a mild infection or are asymptomatic, 15% have mild respiratory failure, and 5% require noninvasive or invasive mechanical ventilation. As of yet, the long-term sequelae of COVID-19 pneumonia are unknown. We report a case of Sars-CoV-2 infection with severe pulmonary involvement in preexisting emphysema.

✩ This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
✩✩ Declarations of competing interest: None.
* Corresponding author.
E-mail address: giulia.angeletti@ausl.bologna.it (G. Angeletti).

https://doi.org/10.1016/j.radcr.2020.11.050
1930-0433/© 2020 Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Fig. 1 – Lung HRCT of the patient with axial images and multiplanar reconstructions. (A) First CT. Bilateral centrilobular emphysema more prominent in the upper right lobe with minimal GGO. (B) Second CT (2 weeks later from the first HRCT). New bilateral peripheral mild ground glass opacities in all lobes. (C) Last CT (7 weeks later from the first CT). More extension of GGO but also evidence of volume loss, distortion of the architecture and traction bronchiectasis due to fibrosis, the latter more evident in the lower lobes. Enlargement of centrilobular emphysema more evident in the upper lobes. The radiological appearance is globally similar to the combined pulmonary fibrosis and emphysema syndrome. GGO, ground glass opacity; HRCT, high resolution computer tomography.

Case report

In March 2020, a 74-year-old woman was admitted to the emergency department for dizziness. Her past medical history was significant for emphysematous chronic obstructive pulmonary disease with smoking habit, severe chronic ischemic heart disease, and hypercholesterolemia. The patient presented with hypoxemic respiratory failure with SpO2 82% and 24/min respiratory frequency in room air and spontaneous
breathing. Oxygen therapy with a Venturi mask was started. The electrocardiogram was negative for ischemia and body temperature was 37.6°C. The laboratory tests revealed lymphopenia and C-reactive protein increase. Chest HRCT was performed showing centrilobular emphysema and 2 ground glass opacity (GGO) areas at the ventral segment of the superior right lobe and at the lateral segment of the middle right lobe (Fig. 1A). The patient was tested for Coronavirus-19 with real-time polymerase chain reaction and resulted positive. She was admitted to the medicine department where therapy with hydroxychloroquine and azithromycin was started. After 7 days from admission the patient deteriorated and was admitted to the intensive care unit and then to our “COVID-19 Sub-ICU” where noninvasive mechanical ventilation (NIMV) was started. Intubation was not indicated because of her severe cardiopulmonary comorbidities. She received 8 mg/kg single dose of tocilizumab and started methylprednisolone 1 mg/kg and enoxaparin 100 U/kg 2 times a day. After 48 hours from tocilizumab administration respiratory failure improved. At 20 days from admission a HRCT (not showed) was repeated and revealed regression of GGO. Arterial blood gasses showed improvement of hypoxemia with arterial oxygen partial pressure/fraction of inspired oxygen (P/F) ratio of 176 mm Hg, allowing the discontinuation of NIMV. High flow oxygen was still required. Clinical conditions deteriorated again a few days later with increasing respiratory frequency and worsening of hypoxemia. A new chest HRCT (Fig. 1B) scan showed increasing basal nonspecific GGOs with sign of loss of volume and traction bronchiectasis. The situation was complicated by a gram-positive sepsis and the patient was treated successfully with linezolid. Subsequently respiratory conditions worsened and NIMV was started again. At 55 days from admission arterial blood gasses showed very severe hypoxic respiratory failure with P/F ratio less than 40 mm Hg. A last chest HRCT (Fig. 1C) scan revealed radiological progression of pulmonary fibrosis at inferior lobes associated with global architecture distortion. Two months from admission the patient died due to severe hypoxic respiratory failure.

Discussion

Evolution of SARS-CoV-19 related pneumonia is still under debate. In the usual course of mild lung involvement, the resolution of consolidations and crazy-paving pattern requires 14 to 30 days after the onset of the initial symptoms. Ground glass opacities are the main findings in the follow up and can be found whereas consolidations were previously observed [2,3]. On the other hand more severe cases may result in persistent lung alterations. Fourteen patients in a Korean observational study [4] showed fibrotic signs due to the SARS-CoV-19 pneumonia, and most frequent alterations reported after discharge were irregular interface and parenchymal bands. In a recent long-term study [5] on the lung consequences of 2003 SARS outbreak, Zhang et al found 31% of patients have radiologic abnormalities at CT scans across 15 years of follow up. Lung abnormalities reported were GGO or cord-like consolidations. Clinical course of our case study was initially quite usual for SARS-Cov-19 with only small GGOs at admission and subsequently development of progressive hypoxemic respiratory failure as the ground glass involvement progressed. We observed initial recovery from the acute phase and a slight improvement in respiratory failure after tocilizumab administration while HRCT scan showed resolution of GGO. After a month from the onset of symptoms a respiratory failure with extremely severe hypoxemia was still present (P/F <40 mm Hg). As the respiratory conditions further worsened the chest HRCT scan showed initial signs of loss of volume associated with progressive lung fibrosis; despite the severity of the condition inflammatory markers were reduced, suggesting a low activity of the SARS-CoV-19-related disease. HRCT scans never showed a clear pattern of ARDS, instead a slow but progressive fibrotic process which after 2 months, unlike the cases cited above, lead to the radiological alterations resembling a pattern of combined pulmonary fibrosis and emphysema. Our findings agree with the considerations suggested by Spagnolo et al[1] of potential development of severe pulmonary fibrosis after SARS-CoV-19 infection.

Conclusion

In our case study, a lung fibrosis overlapping a preexistent emphysema could be a potential lethal complication of COVID-19. Further studies are required to assess risk of development of subacute pulmonary fibrosis in patients with SARS-CoV-19 related pneumonia.

Patient Consent statement

The authors declare that they have acquired the patient’s verbal informed consent for publication of her case; unfortunately she was unable to express written consent due to the severity of the disease.

References

[1] Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12(7):6049–57.
[2] Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020;295(3):715–21.
[3] Adair LB 2nd, Ledermann EJ. Chest CT findings of early and progressive phase COVID-19 infection from a US patient [published online ahead of print, 2020 Apr 20]. Radiol Case Rep 2020;15(7):819–824.
[4] Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol 2020;21(6):746–55.
[5] Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res 2020;8:8.
[6] Spagnolo P, Balestro E, Alberti S, Coccorcelli E, Biondini D, Della Casa G, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med 2020;8:750–2.